AstraZeneca’s (AZN) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by equities research analysts at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, Digital Look reports. They currently have a £117 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential downside of 3.35% from the company’s previous close.

AZN has been the subject of a number of other research reports. Berenberg Bank dropped their price objective on shares of AstraZeneca from £160 to £150 and set a “buy” rating for the company in a report on Tuesday. Royal Bank Of Canada restated an “outperform” rating and issued a £145 price target on shares of AstraZeneca in a research note on Tuesday, September 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, September 9th. Finally, Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of £150.

AstraZeneca Stock Down 0.4%

AZN opened at £121.06 on Tuesday. The company has a 50-day moving average price of £122.84 and a 200 day moving average price of £135.11. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The company has a market cap of £187.75 billion, a PE ratio of 18.12, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. AstraZeneca has a twelve month low of £107.84 and a twelve month high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.